Significant role of Fas ligand-binding but defective Fas receptor (CD95) in lymph node hyperplasia composed of abnormal double-negative T cells

被引:3
|
作者
Matsuzawa, A
Shimizu, M
Takeda, Y
Nagase, H
Sayama, K
Kimura, M
机构
[1] Univ Tokyo, Inst Med Sci, Lab Anim Res Ctr, Minato Ku, Tokyo 108, Japan
[2] Univ Tokyo, Inst Med Sci, Dept Surg, Minato Ku, Tokyo, Japan
[3] Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 113, Japan
[4] Shishu Univ Sch Med, Dept Parasitol, Matsumoto, Nagano, Japan
[5] Shizuoka Univ, Fac Agr, Dept Anim Sci, Ohya, Shizuoka, Japan
[6] Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Shinjuku Ku, Toyama, Japan
关键词
D O I
10.1046/j.1365-2567.2002.01462.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The functional differences between two mutations of the Fas (CD95) locus, Fas(lpr) (lpr) and Fas(lprcg) (lpr(cg) ), were investigated using bone marrow (BM) transplantation on the C3H mouse background. Both lpr/lpr and lpr(cg) /lpr(cg) BM transferred caused lymph node (LN) hyperplasia in lpr/+ and lpr(cg) /+ recipients, although it was clearly smaller than that in lpr/lpr and lpr(cg) /lpr(cg) recipients of lpr/lpr and lpr(cg) /lpr(cg) BM. In addition, both BM induced significantly larger LN hyperplasia in lpr(cg) /+ than lpr/+ recipients. Appearance of CD4(-) CD8(-) [double negative (DN)] T cells in the periphery is the most consistent phenotype of Fas mutations. Importantly, the proportion of DN T cells was higher in larger LN hyperplasia in the order of lpr/+, lpr(cg) /+ and lpr/lpr or lpr(cg) /lpr(cg) recipients. On the other hand, both lpr/lpr and lpr(cg) /lpr(cg) BM transferred into wild-type (+/+) mice caused marked LN atrophy. The former, but not the latter, induced wasting syndrome. Fasl(g1d) (gld)-homozygous lpr/lpr BM transferred into +/+ mice elicited LN hyperplasia of the same extent as that in lpr/lpr mice transferred with lpr/lpr BM, but not wasting syndrome. Taken together with the fact that DN T cells massively express Fas ligand (FasL), this study implied that FasL overexpressed on DN cells may be involved in the accumulation of DN T cells in LN, LN atrophy and wasting syndrome, and that lpr(cg) Fas, which can bind to Fas ligand but not transduce apoptosis signal into cells, may modulate these pathological conditions by interfering with the binding of FasL to Fas.
引用
收藏
页码:470 / 475
页数:6
相关论文
共 50 条
  • [21] Regulation of CD95 (APO-1/Fas) receptor and ligand expression by lipopolysaccharide and dexamethasone in parenchymal and nonparenchymal rat liver cells
    Müschen, M
    Warskulat, U
    Douillard, P
    Gilbert, E
    Häussinger, D
    HEPATOLOGY, 1998, 27 (01) : 200 - 208
  • [22] DEFECTIVE EXPRESSION OF THE APOPTOSIS-INDUCING CD95 (FAS/APO-1) MOLECULE ON T-CELLS AND B-CELLS IN IDDM
    GIORDANO, C
    DEMARIA, R
    STASSI, G
    TODARO, M
    RICHIUSAM, P
    GIORDANO, M
    TESTI, R
    GALLUZZO, A
    DIABETOLOGIA, 1995, 38 (12) : 1449 - 1454
  • [23] Fas (Apo-1/CD95) - Ligand expression on neoplastic plasma cells and its role for the expansion of the neoplastic clone.
    Greil, R
    Villunger, A
    Egle, A
    Marschitz, L
    Kos, M
    Bock, G
    Ludwig, H
    Geley, S
    Kofler, R
    BLOOD, 1997, 90 (10) : 1578 - 1578
  • [24] A distinct CD38+CD45RA+ population of CD4+, CD8+, and double-negative T cells is controlled by FAS
    Maccari, Maria Elena
    Fuchs, Sebastian
    Kury, Patrick
    Andrieux, Geoffroy
    Volkl, Simon
    Bengsch, Bertram
    Lorenz, Myriam Ricarda
    Heeg, Maximilian
    Rohr, Jan
    Jagle, Sabine
    Castro, Carla N.
    Gross, Miriam
    Warthorst, Ursula
    Koenig, Christoph
    Fuchs, Ilka
    Speckmann, Carsten
    Thalhammer, Julian
    Kapp, Friedrich G.
    Seidel, Markus G.
    Duckers, Gregor
    Schoenberger, Stefan
    Schuetz, Catharina
    Fuhrer, Marita
    Kobbe, Robin
    Holzinger, Dirk
    Klemann, Christian
    Smisek, Petr
    Owens, Stephen
    Horneff, Gerd
    Kolb, Reinhard
    Naumann-Bartsch, Nora
    Miano, Maurizio
    Staniek, Julian
    Rizzi, Marta
    Kalina, Tomas
    Schneider, Pascal
    Erxleben, Anika
    Backofen, Rolf
    Ekici, Arif
    Niemeyer, Charlotte M.
    Warnatz, Klaus
    Grimbacher, Bodo
    Eibel, Hermann
    Mackensen, Andreas
    Frei, Andreas Philipp
    Schwarz, Klaus
    Boerries, Melanie
    Ehl, Stephan
    Rensing-Ehl, Anne
    JOURNAL OF EXPERIMENTAL MEDICINE, 2021, 218 (02):
  • [25] Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system
    McGahon, AJ
    Costa Pereira, AP
    Daly, L
    Cotter, TG
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 (03) : 539 - 547
  • [26] Development of a quantitative RT-PCR for the human APO-1 (FAS/CD95) ligand and monitoring of ligand expression in normal and malignant T cells
    Herr, I
    Balemans, L
    Friesen, C
    Debatin, KM
    BLOOD, 1995, 86 (10) : 639 - 639
  • [27] Distinct requirements for activation-induced cell surface expression of preformed Fas/CD95 ligand and cytolytic granule markers in T cells
    Kassahn, D.
    Nachbur, U.
    Conus, S.
    Micheau, O.
    Schneider, P.
    Simon, H-U
    Brunner, T.
    CELL DEATH AND DIFFERENTIATION, 2009, 16 (01): : 115 - 124
  • [28] Distinct requirements for activation-induced cell surface expression of preformed Fas/CD95 ligand and cytolytic granule markers in T cells
    D Kassahn
    U Nachbur
    S Conus
    O Micheau
    P Schneider
    H-U Simon
    T Brunner
    Cell Death & Differentiation, 2009, 16 : 115 - 124
  • [29] Ceramide synthase-6 binding to CD95/Fas confers resistance to chemotherapy in T-cell acute lymphoblastic leukemia cells
    Verlekar, Dattesh U.
    Cho, Hwangeui
    Wei, Sung-Jen
    Kang, Min H.
    CANCER RESEARCH, 2018, 78 (13)
  • [30] Activation-induced apoptosis and cell surface expression of Fas (CD95) ligand are reciprocally regulated by retinoic acid receptor α and γ and involve nur77 in T cells
    Tóth, R
    Szegezdi, É
    Reichert, U
    Bernardon, JM
    Michel, S
    Ancian, P
    Kis-Tóth, K
    Macsári, Z
    Fésüs, L
    Szondy, Z
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2001, 31 (05) : 1382 - 1391